Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGSWW) Non Operating Income (2020 - 2025)

GeneDx Holdings has reported Non Operating Income over the past 6 years, most recently at -$4.0 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$4.0 million for Q4 2025, down 459.52% from a year ago — trailing twelve months through Dec 2025 was -$3.7 million (up 74.75% YoY), and the annual figure for FY2025 was -$8.1 million, up 38.07%.
  • Non Operating Income for Q4 2025 was -$4.0 million at GeneDx Holdings, down from -$174000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for WGSWW hit a ceiling of $121.0 million in Q3 2021 and a floor of -$53.4 million in Q4 2022.
  • Median Non Operating Income over the past 5 years was $71000.0 (2022), compared with a mean of $7.6 million.
  • Biggest five-year swings in Non Operating Income: surged 25350.0% in 2023 and later plummeted 15775.58% in 2024.
  • GeneDx Holdings' Non Operating Income stood at $75.6 million in 2021, then tumbled by 170.58% to -$53.4 million in 2022, then surged by 104.19% to $2.2 million in 2023, then tumbled by 131.95% to -$714000.0 in 2024, then tumbled by 459.52% to -$4.0 million in 2025.
  • The last three reported values for Non Operating Income were -$4.0 million (Q4 2025), -$174000.0 (Q3 2025), and $239000.0 (Q2 2025) per Business Quant data.